The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
Approval strengthens the company’s growing international anti-infective portfolio
This is an exciting and meaningful milestone for GRIN Therapeutics
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Doctors highlight rising respiratory risks linked to pollution, seasonal changes, and poor treatment adherence amid increasing asthma burden in India
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
